The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC).
Arnoud Templeton
No relevant relationships to disclose
Lisa Wang
No relevant relationships to disclose
Francisco Vera-Badillo
No relevant relationships to disclose
Mirna Attalla
No relevant relationships to disclose
Paulo De Gouveia
No relevant relationships to disclose
Raya Leibowitz-Amit
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Srikala S. Sridhar
No relevant relationships to disclose
Anthony Michael Joshua
No relevant relationships to disclose
Ian Tannock
Consultant or Advisory Role - Sanofi (U); Sanofi (U)
Research Funding - Sanofi ; Sanofi ; Sanofi